8-K: Benitec Biopharma Changes Auditors to Ernst & Young

Benitec Biopharma Inc. has dismissed Baker Tilly US, LLP as its independent registered public accounting firm and appointed Ernst & Young LLP as its successor.

Summary

• Benitec Biopharma Inc. has changed its independent registered public accounting firm.
• Baker Tilly US, LLP was dismissed on September 18, 2026, and Ernst & Young LLP (EY) has been appointed as the new auditor.
• The change is described as a matter of good corporate governance.
• Baker Tilly's audit reports for fiscal years ended June 30, 2026, and 2025, were without adverse opinions or qualifications.
• A material weakness in internal control over financial reporting related to share-based compensation was identified and remediated by June 30, 2026.
• EY's appointment is subject to their client acceptance process.
• There were no disagreements or reportable events with Baker Tilly, except for the previously disclosed and remediated material weakness.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, primarily a routine change in auditors with no immediate financial implications disclosed.

Positives

• The company has remediated a previously identified material weakness in internal control over financial reporting related to share-based compensation by June 30, 2026.
• The previous auditor, Baker Tilly, did not issue any adverse opinions or disclaimers of opinion on the company's financial statements for the fiscal years ended June 30, 2026, and 2025.
• The change in auditors is framed as a proactive measure for good corporate governance.

Negatives

• The company previously had a material weakness in internal control over financial reporting concerning the review process for share-based compensation calculations.

Risks

• The appointment of Ernst & Young LLP is contingent upon their completion of a client acceptance process.

Future Outlook

The company has appointed Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending June 30, 2027, subject to EY's client acceptance process.

Management Comments

• As a matter of good corporate governance, the Company completed a process to review the engagement of the Companys independent registered public accounting firm to audit the Companys future consolidated financial statements.

Industry Context

StockSavvy.ai notes that auditor changes are common in the life sciences sector, often occurring after a period of significant financial reporting scrutiny or as part of a company's maturation process. The remediation of internal control weaknesses is a positive step towards enhanced financial transparency.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased confidence in financial reporting due to auditor change and remediation of internal control weaknesses.
• Creditors: Enhanced assurance regarding the accuracy of financial statements.

Next Steps

• Ernst & Young LLP to complete its client acceptance process.
• Ernst & Young LLP to serve as the independent registered public accounting firm for the fiscal year ending June 30, 2027.

Key Dates

Keywords

auditor change, certifying accountant, internal controls, financial reporting, corporate governance, Baker Tilly, Ernst & Young